What CJC-1295 without DAC is, and why it does not inherit the other one's data
In short
CJC-1295 without the drug affinity complex is the same GHRH-analogue backbone with the part that gave it days of duration removed. The three human publications studied the version with the complex, not this one. A PubMed search returns no trial published under this name.
This product is defined by an absence, so that is where to start: it is CJC-1295 without the drug affinity complex.
Why that absence changes everything
The affinity complex was not a cosmetic addition to the other version: it was its entire pharmacology. It is what binds permanently to albumin after injection and what turned a half-life of minutes into one of days [2].
Removing it returns the compound to the starting point that the research itself described as the problem to solve: natural growth-hormone-releasing hormone has a half-life of minutes, and that is exactly what limited its use [1].
Put plainly: the figures on the other page do not apply here. Growth hormone raised for six days, IGF-I elevated for eleven, a half-life of almost eight: all of that was measured on the molecule with the complex. This is a different one.
What has been published on this specific version
Here it is worth being precise about what has been checked and what has not.
A PubMed search carried out on 10 September 2026 returned no clinical trial published under the name "CJC-1295 without DAC". The only indexed publication naming it is a 2026 narrative review that collects the peptides encountered in clinical practice and in the self-administration protocols circulating online, and ranks them by evidence tier: from those with randomised-trial data to those with a complete absence of human studies [4].
That is what can be stated and no more: that it does not appear in that channel. It is not the same as saying nothing exists anywhere.
That same review also describes the adverse effects reported with this family of compounds — endocrine and metabolic disturbances, including raised prolactin and cortisol, appetite changes and dysglycaemia, fluid retention, muscle and joint pain, and injection-site reactions — and notes that uncertainty about the real composition of the products is part of the problem [4].
What does not exist
There is no approved indication, no phase 3 trials and no long-term safety data in people.
This page describes published literature. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional.
What to look at when comparing suppliers
- That the supplier distinguishes the two versions and says which one they sell. Anyone treating them as the same thing either does not know, or is counting on the buyer not knowing.
- Be wary of figures from the DAC version used to sell this one. It is the most common error with this product and it is checkable: just look at which molecule the cited paper studied.
- Identity confirmation by mass spectrometry and HPLC purity for the specific batch.
References
- [1] Teichman S.L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID 16352683 View source
- [2] Ionescu M., Frohman L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PMID 17018654 View source
- [3] Sackmann-Sala L. et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. PMID 19386527 View source
- [4] Dominikowski A. et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. PMID 42395176 View source
This page reports what has been published in the scientific literature about a research molecule. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional. The product is sold strictly for in vitro research.
It is also inside: